MELANOMA STAGE IV
Clinical trials for MELANOMA STAGE IV explained in plain language.
Never miss a new study
Get alerted when new MELANOMA STAGE IV trials appear
Sign up with your email to follow new studies for MELANOMA STAGE IV, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a rheumatoid arthritis drug tame immunotherapy side effects?
Disease control OngoingThis study tests whether infliximab, a drug used for inflammatory conditions, can treat colitis (colon inflammation) caused by immune checkpoint inhibitors in people with stage III or IV skin cancer. About 42 participants will receive either infliximab or steroids, and researcher…
Matched conditions: MELANOMA STAGE IV
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New PET scan may reveal if immunotherapy is working in melanoma
Disease control OngoingThis phase 2 trial is testing whether giving two immunotherapy drugs, nivolumab and ipilimumab, before surgery can shrink stage III melanoma tumors and prevent the cancer from returning. The 28 participants will also receive an experimental PET scan that images immune cells to se…
Matched conditions: MELANOMA STAGE IV
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug ST101 takes on Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…
Matched conditions: MELANOMA STAGE IV
Phase: PHASE1, PHASE2 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New drug aims to unmask melanoma to the immune system
Disease control OngoingThis early-stage trial tests a new oral drug, SX-682, combined with the immunotherapy pembrolizumab in people with advanced melanoma. The goal is to see if SX-682 can stop cancer from hiding from the immune system, making the immunotherapy work better. About 77 participants will …
Matched conditions: MELANOMA STAGE IV
Phase: PHASE1 • Sponsor: Syntrix Biosystems, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
DNA vaccines aim to supercharge immune therapy against skin cancer
Disease control OngoingThis phase 2 trial is testing two experimental DNA vaccines, SCIB1 and iSCIB1+, in combination with standard immunotherapy drugs for people with advanced melanoma that cannot be removed by surgery. The study involves 173 participants and aims to see if adding these vaccines is sa…
Matched conditions: MELANOMA STAGE IV
Phase: PHASE2 • Sponsor: Scancell Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New combo therapy aims to shrink melanoma before surgery
Disease control OngoingThis study tests whether giving one or two immunotherapy drugs before surgery can shrink advanced melanoma (stage III or IV) that can be removed. About 48 adults with operable melanoma will receive either a single drug (dostarlimab) or a combination (dostarlimab plus cobolimab) b…
Matched conditions: MELANOMA STAGE IV
Phase: PHASE2 • Sponsor: Diwakar Davar • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New hope for patients with rare brain lining cancer spread
Disease control OngoingThis early-phase study tests a new way to give immunotherapy drugs (nivolumab and ipilimumab) for patients with lung cancer or melanoma that has spread to the lining of the brain and spinal cord (leptomeningeal metastases). The drugs are given both directly into the spinal fluid …
Matched conditions: MELANOMA STAGE IV
Phase: PHASE1 • Sponsor: University of Zurich • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New combo shows promise against tough skin cancer
Disease control OngoingThis phase 2 trial tests whether adding an experimental drug (EVX-01) to standard immunotherapy (pembrolizumab) can shrink tumors better than pembrolizumab alone in people with advanced melanoma that cannot be removed by surgery. Seventeen adults who have never received checkpoin…
Matched conditions: MELANOMA STAGE IV
Phase: PHASE2 • Sponsor: Evaxion Biotech A/S • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Melanoma survivors: new study tracks immunotherapy side effects
Knowledge-focused OngoingThis study follows 126 melanoma survivors who are receiving immunotherapy after surgery. Researchers will track side effects and quality of life for up to 24 months. They will also collect blood samples to look for markers that might predict who gets side effects. The goal is to …
Matched conditions: MELANOMA STAGE IV
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC